--BioArctic AB's partner Eisai today announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has reaffirmed its positive opinion for the anti-Aβ ...

The opinion will now be referred to the European Commission for final regulatory decision on donanemab  INDIANAPOLIS, July 25 ...

The European Medicines Agency’s human medicines committee has recommended that BeOne Medicines’ Tevimbra (tislelizumab) be ...

Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for ...

Committee For Medicinal Products For Human Use Post-Authorisation Summary Of Positive Opinion For Xolair International Nonproprietary Name (INN): omalizubam LONDON, June 25, 2009-On 25 June 2009 the ...

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SUMMARY OF POSITIVE OPINION for Pioglitazone/ metformin hydrochloride Takeda 15 mg/850 mg film-coated tablets International Nonproprietary Name (INN): ...

Press Releases EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1 ...

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 January 2014 By Emily Wasserman Jan 24, 2014 7:35am Pharma ...

TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025/ PRNewswire/-- Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency ...

The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer's disease in the EU Provided by PR Newswire Feb 28, 2025 5:11am ...

EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of the Moderna COVID-19 Vaccine in Adolescents (12-17 Years of Age) in the ...